308 related articles for article (PubMed ID: 18780323)
1. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
[TBL] [Abstract][Full Text] [Related]
4. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
[TBL] [Abstract][Full Text] [Related]
5. [The occurrence of anemia in small cell lung cancer patients during first-line chemotherapy].
Swiatoniowski G; Bruzewicz S; Bronowicz Z; Kłaniewski T
Pol Merkur Lekarski; 2009 Feb; 26(152):98-100. PubMed ID: 19388511
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
7. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
8. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period.
Hansen O; Sørensen P; Hansen KH
Lung Cancer; 2010 Apr; 68(1):111-4. PubMed ID: 19535164
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in patients with inoperable non-small cell lung cancer--an analysis of long-term survival patients.
Ohashi R; Takahashi K; Miura K; Ishiwata T; Sakuraba S; Fukuchi Y
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1595-602. PubMed ID: 17108725
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
Mountzios G; Bamias A; Voulgaris Z; Rodolakis A; Vlahos G; Gourgoulis G; Papaiakovou EE; Giannopoulos A
Gynecol Oncol; 2008 Jan; 108(1):130-5. PubMed ID: 17988722
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
12. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
13. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
14. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Su Y
Ai Zheng; 2006 Dec; 25(12):1569-72. PubMed ID: 17166389
[TBL] [Abstract][Full Text] [Related]
16. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.
Christodolou C; Pavlidis N; Samantas E; Fountzilas G; Kouvatseas G; Pagdatoglou K; Palamidas F; Nikolaidis C; Angelidou M; Kalofonos HP; Kosmidis P; Skarlos DV
Anticancer Res; 2002; 22(6B):3749-57. PubMed ID: 12552988
[TBL] [Abstract][Full Text] [Related]
18. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
19. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
Zang R; Zhang Z; Cai S
Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
[TBL] [Abstract][Full Text] [Related]
20. Third-line chemotherapy for small cell lung cancer.
de Jong WK; ten Hacken NH; Groen HJ
Lung Cancer; 2006 Jun; 52(3):339-42. PubMed ID: 16564112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
